Form 8K Atrium Therapeutics Inc For: 2 November
- Investing.com
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Atrium Therapeutics Inc (RNA)
Track today's live Atrium Therapeutics (RNA) share price, performance and key data on this page with our current NASDAQ:RNA stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Atrium Therapeutics share price on the NASDAQ exchange. Use the dropdown to switch exchange for the RNA share price, head to our technical summary section, which provides analysis on Atrium Therapeutics share price buy/sell indicators using real-time data (or discuss the Atrium Therapeutics (RNA) stock price today with other investors in the Atrium Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:RNA share price (ISIN: US04965N1046) to enhance your trading decisions with our free investment tools and resources.
What Is the Atrium Therapeutics Inc Share Price Today?
The Atrium Therapeutics share price today is 8.32.
What Is the Stock Symbol for Atrium Therapeutics Inc
The stock symbol (or 'ticker') for Atrium Therapeutics Inc is "RNA."
What Stock Exchange Does Atrium Therapeutics Inc Trade On?
Atrium Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Atrium Therapeutics Inc a Good Stock to Buy?
Determining whether Atrium Therapeutics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:RNA share price (ISIN: US04965N1046) to enhance your trading decisions with our free investment tools and resources.
What Is the Atrium Therapeutics Inc Share Price Today?
The Atrium Therapeutics share price today is 8.32.
What Is the Stock Symbol for Atrium Therapeutics Inc
The stock symbol (or 'ticker') for Atrium Therapeutics Inc is "RNA."
What Stock Exchange Does Atrium Therapeutics Inc Trade On?
Atrium Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Atrium Therapeutics Inc a Good Stock to Buy?
Determining whether Atrium Therapeutics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.29
8.73
52 wk Range
7.49
16.77
RNA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.298.73
52 wk Range
7.4916.77
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RNA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
22.00
Upside
+164.42%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Form 8K Atrium Therapeutics Inc For: 27 October- Investing.com
- Form 8K Atrium Therapeutics Inc For: 2 November
- Investing.com
- Form 8K Atrium Therapeutics Inc For: 27 October
- Investing.com
Atrium doses first patient in PRKAG2 syndrome trial- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 22.00
(+164.42% Upside)
Earnings
Latest Release
13/08/2026
EPS / Forecast
-1.18 / --
Revenue / Forecast
3M / --
Compare RNA to Peers and Sector
Metrics to compare | RNA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRNAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.2x | −15.0x | −0.2x | |
PEG Ratio | - | −0.12 | 0.00 | |
Price/Book | 0.7x | 3.5x | 2.6x | |
Price / LTM Sales | 4.0x | 3.4x | 2.8x | |
Upside (Analyst Target) | 164.4% | 159.7% | 62.1% | |
Fair Value Upside | Unlock | 19.5% | 9.5% | Unlock |
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company’s development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California. Atrium Therapeutics, Inc. was formerly a subsidiary of Avidity Biosciences, Inc.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Atrium Therapeutics (NASDAQ: RNA) Share Price Today?
The Atrium Therapeutics stock price today is 8.32 USD.
What Stock Exchange Does Atrium Therapeutics (RNA) Trade On?
Atrium Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Atrium Therapeutics?
The stock symbol (also called a 'ticker') for Atrium Therapeutics is "RNA."
What Is the Current Atrium Therapeutics Market Capitalisation?
As of today, Atrium Therapeutics (NASDAQ: RNA) market cap is 142.32M USD.
What Is Atrium Therapeutics's (RNA) Earnings Per Share (TTM)?
The Atrium Therapeutics EPS is currently -3.86 (Trailing Twelve Months).
When Is the Next Atrium Therapeutics Earnings Date?
Atrium Therapeutics's next earnings report will be released on 02/12/2026.
Is RNA a Buy or Sell From a Technical Analyst Perspective?
Based on today's Atrium Therapeutics moving averages and other technical indicators, the daily buy/sell signal for RNA stock is Neutral.
How Many Times Has Atrium Therapeutics Stock Split?
Atrium Therapeutics has split 0 times. (See the RNA stock split history page for full effective split date and price information.)
What is the current trading status of Atrium Therapeutics (NASDAQ: RNA)?
As of 06/11/2026, Atrium Therapeutics (RNA) is trading at a share price of 8.32 USD, with a previous close of 8.32 USD. The stock has fluctuated within a day range of 8.29 USD to 8.73 USD, while its 52-week range spans from 7.49 USD to 16.77 USD.
What Is Atrium Therapeutics (RNA) Price Target According to Analysts?
The average 12-month price target for Atrium Therapeutics is 22.00 USD, with a high estimate of 25 USD and a low estimate of 15 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +164.42% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.